aripiprazole - Page 1 | CARLAT PUBLISHING

Research Update

Strategies to Reduce Antipsychotic-Induced Hyperprolactinemia

January 1, 2025

Sarah Azarchi, MD

Sarah Azarchi, MD. Dr. Azarchi has no financial relationships with companies related to this material.

Five strategies to reduce prolactin on antipsychotics tested in this meta-analysis

Optimal Abilify Dose for Depression (MDD Augmentation with Aripiprazole)

August 13, 2024

Richard Moldawsky, MD and Greg Malzberg, MD

This video breaks down the findings from a meta-analysis of randomized controlled trials, examining how aripiprazole dosage impacts patient outcomes in clinical depression treatment.

Research Update

Long-Acting Injectable Antipsychotics and Risk of Hospitalization

October 3, 2023

Brian Holoyda, MD, MPH, MBA

Brian Holoyda, MD. Dr. Holoyda has no financial relationships with companies related to this material.

By initiating LAIs early in the course of a patient’s illness, we can significantly delay the time to first hospitalization in young adults.

Research Update

Antipsychotics in Pregnancy and Risk of Neurodevelopmental Disorders

October 3, 2023

Sébastien Hardy, PharmD, BCPS.

Sébastien Hardy, PharmD, BCPS. Dr. Hardy has no financial relationships with companies related to this material.

This large study gives us reassuring data about neurodevelopmental outcomes in children exposed to several second-generation antipsychotic medications during pregnancy.

Clinical Update

Treating Irritability in Autism: Functional and Medication Approaches

April 1, 2023

Joshua Feder, MD

Joshua D. Feder, MD. Editor-in-Chief, The Carlat Child Psychiatry Report.

Dr. Feder has no financial relationships with companies related to this material.

Antipsychotics can be very effective for irritability in autism, but they are often unnecessary, and the side effects are truly problematic. Don’t be the prescriber who hears irritability in autism and immediate prescribes antipsychotics. There are usually multiple steps to try before using the FDA approved antipsychotic medications.

RESEARCH UPDATE

Aripiprazole-Related Psychotic Exacerbations

January 1, 2023

Brian Miller, MD, PhD, MPH.

Brian Miller, MD, PhD, MPH. Dr. Miller, author of this educational activity, receives research support from Augusta University, the National Institute of Mental Health, the Brain and Behavior Research Foundation, and the Stanley Medical Research Institute. Relevant financial relationships listed for the author have been mitigated.

This study identifies a common clinical scenario where aripiprazole may trigger psychotic symptoms.

Aripiprazole in Depression: The Right Dose

September 25, 2022

Richard Moldawsky, MD

Richard Moldawsky, MD. Dr. Moldawsky has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Dosing recommendations for aripiprazole vary widely in depression, from 2 mg to 15 mg, but this meta-analysis finds a sweet spot in the lower range.

EXPERT Q&A

The Schizophrenia-OCD Overlap

September 28, 2021

Michael Poyurovsky, MD

Michael Poyurovsky, MD

Ma’ale HaCarmel Mental Health Center, Tirat Carmel, Israel; Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel. Dr. Poyurovsky has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

OCD and schizophrenia often overlap, but treatment of this comorbidity is risky terrain. Dr. Poyurovsky explains when antidepressants should be avoided and details which antipsychotics are more likely to exacerbate OCD and which ones are more likely to help it.

Medications to Rapidly Treat Psychotic Agitation

September 13, 2021

Daniel Carlat, MD

Victoria Hendrick, MD. Editor in Chief, The Carlat Hospital Psychiatry Report. Chief, Inpatient Psychiatry, Olive View UCLA Medical Center.

Daniel Carlat, MD. Publisher, The Carlat Hospital Psychiatry Report.

Dr. Hendrick and Dr. Carlat have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

How do you choose medications to calm an acutely psychotic and agitated patient? We'll tell you which ones are the safest and most effective.

Battle of the Bulge: Obesity and Antipsychotic-Induced Weight Gain

July 14, 2021

Farah Khorassani, PharmD. Clinical Assistant

Farah Khorassani, PharmD. Clinical Assistant Professor of Pharmacy Practice, St. John’s University, Queens, NY. Dr. Khorassani has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

With so many weight loss medications on the market, it’s hard to know which to choose. Dr. Khorassani tells us everything we need to know to about selecting and prescribing these agents. Also, she gives us additional tips for managing antipsychotic-induced weight gain.